Company's disclaimers:no more complaint again because we tell...

Company's disclaimers:

no more complaint again because we tell you everything of our risks.

"Key risk factors

In assessing this offer, shareholders should consider the risks associated with an investment
in Ventracor. Some of the risk factors that should be considered are summarised below:
Funding risk The Company may be unable to secure on acceptable terms, or at all, the
future funding it requires to commercialise the VentrAssist LVAD,
particularly given the current uncertain and volatile economic climate and
equity markets. Failure to secure further funding will have a material
adverse impact on investments in Ventracor.
Investment risk An investment in Ventracor should be considered speculative and is
subject to risks associated with general share market conditions,
economic conditions, inflation, currency fluctuation, interest rates, supply
and demand and changes to legislation and other such commercial
factors. The share price of Ventracor may move up or down.
Regulatory risk There is no guarantee that the necessary regulatory approvals will be
obtained or that there will not be a delay in obtaining such approvals.
Delays could arise from increased competition for clinical trial sites and
patients which inhibits the recruitment rate in the Ventracor~{!/~}s trials. Delay
in FDA regulatory approval will adversely affect the Company~{!/~}s ability to
generate significant revenues in the United States.
Product risk There is a risk that the VentrAssist LVAD may not meet the performance
objectives necessary for regulatory approval, or may be subject to design
or manufacturing issues which could result in a recall or suspension of
sales.
Clinical risk The conduct of a clinical trial requires the engagement of many hospitals,
and clinicians at those hospitals, and good patient selection, all which are
out of Ventracor's control. Adverse events with a patient in a clinical trial
may also be incorrectly ascribed to Ventracor's products. Failure of a
physician to follow the instructions for use of Ventracor's products may
also result in adverse clinical outcomes.
A number of clinical trial and regulatory steps to be taken are outside of
the direct control of the Company and may ultimately follow a course
which is different from historical precedents upon which the chart is
based. In addition, unforeseen circumstances might impact upon
envisaged timeframes for both the clinical trials and the regulatory
approval processes.
Module A of the EVERLAST DT Trial is the first clinical trial of an LVAD in
the US on a ~{!0~}less sick~{!1~} patient population. As such, the Company is
breaking new clinical and regulatory ground, with unknown results. The
Company is at an early stage of enrolment in the EVERLAST Trial, and it
is possible that enrolment may not be as fast as planned or anticipated.
Risk that market
for LVADs does
not develop
The anticipated market for LVADs may not grow to a size whereby
Ventracor can achieve a commercial return from funds provided by its
shareholders.
Competition Competition from other medical device companies or other technology
which may provide a substitute for Ventracor~{!/~}s product(s) may affect the viability of Ventracor as a business.
The occurrence of any or all of the matters referred to above, and others, could have a
material adverse impact on an investment in Ventracor.
You should also be aware that the market price of Ventracor shares may rise or fall between
the date of this offer and the date when shares are issued to you under the Plan, any such
change in the market price of shares will not affect the Issue Price under the Plan or the
number of shares offered to you under the Plan, and the Issue Price may be either higher or
lower than the price of Ventracor's shares at the time the shares are issued to you under the Plan."

-----------Means if you are gathering capital the later lose money, please do not scold the company, is consequence which you have only self to blame.